GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NewAmsterdam Pharma Co NV (NAS:NAMS) » Definitions » GF Value

NewAmsterdam Pharma Co NV (NewAmsterdam Pharma Co NV) GF Value : $0.00 (As of May. 25, 2024)


View and export this data going back to 2022. Start your Free Trial

What is NewAmsterdam Pharma Co NV GF Value?

The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:

  1. Historical multiples (PE Ratio, PS Ratio, PB Ratio and Price-to-Free-Cash-Flow) that the stock has traded at.
  2. GuruFocus adjustment factor based on the company’s past returns and growth.
  3. Future estimates of the business performance.

We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.

Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

As of today (2024-05-25), NewAmsterdam Pharma Co NV's share price is $18.82. NewAmsterdam Pharma Co NV's GF Value is $0.00. Therefore, NewAmsterdam Pharma Co NV's Price-to-GF-Value for today is .

Based on the relationship between the current stock price and the GF Value, GuruFocus believes NewAmsterdam Pharma Co NV is Not Valued.


NewAmsterdam Pharma Co NV  (NAS:NAMS) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

Posssible Evaluations All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)Predictable Companies that possibly be Value Traps
Significantly OvervaluedPredictable Companies which are Significantly Overvalued
Modestly OvervaluedPredictable Companies which are Modestly Overvalued
Fairly ValuedPredictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) There is only a sufficient margin of safety when the stock is undervalued.

NewAmsterdam Pharma Co NV's Price-to-GF-Value for today is calculated as

Price-to-GF-Value=Share Price/GF Value
=18.82/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NewAmsterdam Pharma Co NV GF Value Related Terms

Thank you for viewing the detailed overview of NewAmsterdam Pharma Co NV's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.


NewAmsterdam Pharma Co NV (NewAmsterdam Pharma Co NV) Business Description

Traded in Other Exchanges
Address
Gooimeer 2-35, Naarden, NH, NLD, 1411 DC
NewAmsterdam Pharma Co NV is a clinical-stage company focused on the research and development of transformative therapies for metabolic diseases and Alzheimer's disease.

NewAmsterdam Pharma Co NV (NewAmsterdam Pharma Co NV) Headlines

From GuruFocus

NewAmsterdam Pharma Appoints John W. Smither to its Board of Directors

By Stock market mentor Stock market mentor 02-06-2023